Bluejay Diagnostics, Inc. 8K

Bluejay Diagnostics completed ahead of plan the 750-patient enrollment in its pivotal SYMON-II study of the Symphony IL-6 sepsis mortality risk test, advancing its regulatory and commercialization strategy.

Bluejay Diagnostics, Inc. announced that it has successfully completed enrollment, ahead of schedule, of 750 patients in its pivotal SYMON-II multicenter clinical validation study evaluating the Symphony IL-6 rapid diagnostic test for early assessment of 28‑day sepsis mortality risk in ICU patients, providing a robust dataset expected to support forthcoming data analysis, regulatory submissions (including a planned 510(k) to the FDA), and eventual commercialization efforts for the Symphony platform.

Filing Facts

CIK

1704287

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-080474

Alert Tier

6